Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate

The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of Leishmania parasites (all groups). There was a significant increase of antimony concentration from 0.76 µg/kg wet organ (4 days after the first dose) to 2.07 µg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow. Treatment with LMA significantly reduced the number of dogs positive for parasites (with at least one amastigote per 1000 host cells) compared to controls (positive dogs 30 days after treatment: 0 of 9 in the LMA group, 3 of 9 in the group treated with empty liposomes and 3 of 8 in the untreated group). However, complete elimination of parasites was not achieved. In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites.

Saved in:
Bibliographic Details
Main Authors: Schettini,D.A., Costa Val,A.P., Souza,L.F., Demicheli,C., Rocha,O.G.F., Melo,M.N., Michalick,M.S.M., Frézard,F.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2005
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200017
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2005001200017
record_format ojs
spelling oai:scielo:S0100-879X20050012000172005-11-09Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniateSchettini,D.A.Costa Val,A.P.Souza,L.F.Demicheli,C.Rocha,O.G.F.Melo,M.N.Michalick,M.S.M.Frézard,F. Liposome Meglumine antimoniate Pharmacokinetics Leishmaniasis Dogs Bone marrow The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of Leishmania parasites (all groups). There was a significant increase of antimony concentration from 0.76 µg/kg wet organ (4 days after the first dose) to 2.07 µg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow. Treatment with LMA significantly reduced the number of dogs positive for parasites (with at least one amastigote per 1000 host cells) compared to controls (positive dogs 30 days after treatment: 0 of 9 in the LMA group, 3 of 9 in the group treated with empty liposomes and 3 of 8 in the untreated group). However, complete elimination of parasites was not achieved. In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.38 n.12 20052005-12-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200017en10.1590/S0100-879X2005001200017
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Schettini,D.A.
Costa Val,A.P.
Souza,L.F.
Demicheli,C.
Rocha,O.G.F.
Melo,M.N.
Michalick,M.S.M.
Frézard,F.
spellingShingle Schettini,D.A.
Costa Val,A.P.
Souza,L.F.
Demicheli,C.
Rocha,O.G.F.
Melo,M.N.
Michalick,M.S.M.
Frézard,F.
Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
author_facet Schettini,D.A.
Costa Val,A.P.
Souza,L.F.
Demicheli,C.
Rocha,O.G.F.
Melo,M.N.
Michalick,M.S.M.
Frézard,F.
author_sort Schettini,D.A.
title Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
title_short Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
title_full Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
title_fullStr Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
title_full_unstemmed Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
title_sort pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
description The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of Leishmania parasites (all groups). There was a significant increase of antimony concentration from 0.76 µg/kg wet organ (4 days after the first dose) to 2.07 µg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow. Treatment with LMA significantly reduced the number of dogs positive for parasites (with at least one amastigote per 1000 host cells) compared to controls (positive dogs 30 days after treatment: 0 of 9 in the LMA group, 3 of 9 in the group treated with empty liposomes and 3 of 8 in the untreated group). However, complete elimination of parasites was not achieved. In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites.
publisher Associação Brasileira de Divulgação Científica
publishDate 2005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200017
work_keys_str_mv AT schettinida pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT costavalap pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT souzalf pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT demichelic pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT rochaogf pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT melomn pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT michalickmsm pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
AT frezardf pharmacokineticandparasitologicalevaluationofthebonemarrowofdogswithvisceralleishmaniasissubmittedtomultipledosetreatmentwithliposomeencapsulatedmeglumineantimoniate
_version_ 1756391131693711360